Corbus Pharmaceuticals Holdings, Inc.
(NASDAQ : CRBP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. 0.71%579.812.7%$671.17m
AMGNAmgen, Inc. -0.36%227.161.3%$582.50m
GILDGilead Sciences, Inc. 0.20%60.791.0%$581.98m
VRTXVertex Pharmaceuticals, Inc. 0.71%211.581.9%$512.07m
ILMNIllumina, Inc. -0.73%323.553.5%$494.75m
MRNAModerna, Inc. -0.44%70.530.0%$473.04m
ARRYArray BioPharma Inc. -4.42%42.0014.2%$403.84m
IMMUImmunomedics, Inc. 0.00%87.8611.0%$392.45m
NVAXNovavax, Inc. -0.49%93.1396.5%$309.58m
ALXNAlexion Pharmaceuticals, Inc. 1.62%121.612.0%$277.29m
BIIBBiogen, Inc. -0.68%265.001.7%$264.24m
EXASEXACT Sciences Corp. 2.44%109.7020.7%$241.86m
BNTXBioNTech SE 2.70%88.690.0%$221.27m
SRNESorrento Therapeutics, Inc. -2.42%8.081.4%$162.95m
SGENSeagen Inc. -1.86%196.926.0%$157.61m

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.